PHILADELPHIA, April 28, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Solaris Energy Infrastructure, Inc. ("Solaris" or the "Company") (NYSE: SEI) on behalf of purchasers of Solaris securities between July 9, 2024 through March 17, 2025, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired Solaris securities during the Class Period may, no later than MAY 27, 2025, seek to be appointed as a lead plainti ...

Core Viewpoint - A securities class action lawsuit has been filed against BigBear.ai Holdings, Inc. for alleged accounting deficiencies and misstatements during the Class Period from March 31, 2022, to March 25, 2025 [1][4]. Company Overview - BigBear.ai Holdings, Inc. is an AI-driven technology company based in McLean, VA, specializing in national security, supply chain management, and digital identity and biometrics solutions [3]. - The company went public through a business combination with GigCapital4, Inc. in December 2021 and issued $200 million in convertible notes maturing on December 15, 2026 [3]. Allegations and Financial Impact - The lawsuit alleges that BigBear failed to disclose deficiencies in its accounting review policies and incorrectly accounted for the conversion option within its 2026 Notes, violating Accounting Standards Codification [4]. - On March 18, 2025, BigBear announced that certain financial statements since fiscal year 2021 would be restated, leading to a stock price drop of $0.52 per share (14.9%) to close at $2.97 [5]. - Following the filing of its 2024 10-K on March 25, 2025, which confirmed the misclassification of the conversion option and identified a material weakness in internal controls, the stock price fell an additional $0.32 per share (9.11%) to close at $3.19 [6][7].

Core Viewpoint - A securities class action lawsuit has been filed against AppLovin Corporation for allegedly misleading investors about its financial growth and stability during the Class Period from May 10, 2023, to March 26, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of purchasers of AppLovin securities during the specified Class Period [1]. - Investors have until May 5, 2025, to seek appointment as lead plaintiff [2]. Group 2: Allegations Against AppLovin - The complaint claims that AppLovin and its senior management misled investors regarding the launch of its AXON 2.0 digital ad platform and the use of advanced AI technologies [3]. - Reports from analysts Fuzzy Panda and Culper Research accused AppLovin of reverse-engineering advertising data from Meta Platforms and using manipulative practices to inflate ad click-through and app download rates [4]. - Muddy Waters Research later alleged that AppLovin violated terms of service of major platforms like Facebook and Google, which could threaten its revenue growth sustainability [6]. Group 3: Stock Price Impact - Following the negative reports, AppLovin's stock price dropped from $377.06 on February 25, 2025, to $331.00 on February 26, 2025, marking a decline of $46.06 per share, or 12% [5]. - On March 27, 2025, the stock fell further by $65.92 per share, or 20%, closing at $261.70 after a report from Muddy Waters Research [7].

Core Viewpoint - A securities class action lawsuit has been filed against Zynex, Inc. for allegedly misleading investors regarding its revenue practices and product shipments during the class period from March 13, 2023, to March 11, 2025 [1][3] Company Overview - Zynex, Inc. is a medical device company based in Englewood, CO, specializing in electrotherapy devices for pain management and rehabilitation [2] Allegations in the Lawsuit - The lawsuit claims that Zynex shipped products, including electrodes, in excess of demand, which allowed the company to inflate its revenue [3] - It is alleged that Zynex's practice of filing false claims attracted scrutiny from insurers, including Tricare [3] - The lawsuit suggests that Zynex is likely to face adverse consequences, such as removal from insurer networks and potential penalties from the federal government [3] Investor Information - Investors who purchased Zynex securities during the class period have until May 19, 2025, to seek appointment as a lead plaintiff representative of the class [2][4]

Core Viewpoint - A securities class action lawsuit has been filed against AppLovin Corporation, alleging misleading information regarding its financial growth and the launch of its AXON 2.0 digital ad platform [1][3]. Group 1: Lawsuit Details - The lawsuit covers purchasers of AppLovin securities from May 10, 2023, to March 26, 2025 [1]. - Investors have until May 5, 2025, to seek appointment as lead plaintiff [2]. - Allegations include misleading investors about financial stability and growth, particularly concerning the use of AI technologies [3]. Group 2: Emerging Truths - Reports from analysts Fuzzy Panda and Culper Research on February 26, 2025, accused AppLovin of manipulating advertising data and inflating ad metrics [4]. - Following these reports, AppLovin's stock price dropped from $377.06 to $331.00, a decline of $46.06 or 12% [5]. Group 3: Additional Allegations - On March 26, 2025, Muddy Waters Research published a report alleging that AppLovin violated terms of service of major platforms, threatening its revenue sustainability [6]. - The stock fell further by $65.92 or 20%, closing at $261.70 on March 27, 2025 [7].

Core Viewpoint - A securities class action lawsuit has been filed against TransMedics Group, Inc. for allegedly misleading investors and failing to disclose critical issues during the Class Period from February 28, 2023, to January 10, 2025 [1][3]. Company Overview - TransMedics Group, Inc. is a medical technology company based in Andover, Massachusetts, specializing in transplant services, including its Organ Care System (OCS), which is a portable organ preservation system [2]. Allegations - The lawsuit claims that TransMedics engaged in unethical practices, including using kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue [3]. - It is also alleged that the company concealed safety issues and lacked proper safety oversight within its operations [3]. Impact of Revelations - On February 21, 2024, U.S. Rep. Paul Gosar accused TransMedics of misappropriating corporate resources, leading to a stock price drop of $2.18 per share (2.5%) to close at $84.81 on February 22, 2024 [4]. - Following a report from Scorpion Capital on January 10, 2025, which accused TransMedics of overbilling hospitals and providing rejected organs, the stock fell by $3.74 per share (5%) to close at $68.81, and then further declined by $4.76 per share (6.9%) to close at $64.05 on January 13, 2025 [5].

Core Viewpoint - A securities class action lawsuit has been filed against AppLovin Corporation for alleged manipulative practices and exploitation of advertising data, leading to a significant decline in stock price [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of purchasers of AppLovin securities from May 10, 2023, to February 25, 2025 [1]. - Investors have until May 5, 2025, to seek appointment as lead plaintiff [2]. Group 2: Allegations Against AppLovin - Analysts have accused AppLovin of reverse-engineering advertising data from Meta Platforms and inflating ad click-through and app download rates [3]. - The reports suggest that AppLovin presented false installation numbers and profits through these practices [3]. Group 3: Stock Price Impact - Following the allegations, AppLovin's stock price fell from $377.06 on February 25, 2025, to $331.00 on February 26, 2025, marking a decline of $46.06 per share, or 12% [4].

Core Viewpoint - A securities class action lawsuit has been filed against TransMedics Group, Inc. for allegedly misleading investors regarding business practices and safety issues during the Class Period from February 28, 2023, to January 10, 2025 [1][3]. Company Overview - TransMedics Group, Inc. is a medical technology company based in Andover, Massachusetts, specializing in transplant services, including the Organ Care System (OCS), which is a portable organ preservation system [2]. Allegations - The lawsuit claims that TransMedics engaged in unethical practices, including kickbacks, fraudulent overbilling, and coercive tactics to generate revenue [3]. - It is also alleged that the company concealed safety issues and lacked proper safety oversight [3]. Impact on Stock Price - Following the revelation of these allegations, TransMedics' stock price dropped significantly. On February 22, 2024, the stock fell by $2.18 (2.5%) to close at $84.81 after a letter from U.S. Rep. Paul Gosar accused the company of misappropriating resources [4]. - On January 10, 2025, after a report from Scorpion Capital, the stock fell by $3.74 (5%) to close at $68.81, and further declined by $4.76 (6.9%) to close at $64.05 on January 13, 2025 [5].

PHILADELPHIA, March 5, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) on behalf of purchasers of Regeneron securities between November 2, 2023 through October 30, 2024, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired REGENERON securities during the Class Period may, no later than MARCH 10, 2025, seek to be appointed as a ...